What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study

View Full Paper

Ask AI

Bookmark

Authors

Prospective phase II study shows 86% CCR and significant safety profile in R/R AML, indicating enhanced HSCT opportunities.

The CCR rate after treatment with venetoclax plus CAG was 86%, indicating effective remission for R/R AML.
Of the evaluated patients, 43 achieved CCR, and the overall incidence of grade 3 or higher adverse events was 88.2%.
Assessment involved 51 patients enrolled at Peking University, focusing on efficacy and safety outcomes over a median follow-up of 391.5 days.
These findings highlight the potential of venetoclax plus CAG regimen as a new treatment approach in R/R AML.

Yu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Prospective phase II study shows 86% CCR and significant safety profile in R/R AML, indicating enhanced HSCT opportunities.

The CCR rate after treatment with venetoclax plus CAG was 86%, indicating effective remission for R/R AML.
Of the evaluated patients, 43 achieved CCR, and the overall incidence of grade 3 or higher adverse events was 88.2%.
Assessment involved 51 patients enrolled at Peking University, focusing on efficacy and safety outcomes over a median follow-up of 391.5 days.
These findings highlight the potential of venetoclax plus CAG regimen as a new treatment approach in R/R AML.

Yu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark